The aim of this project, which was commissioned by NICE through the NIHR HTA Programme as part of the NICE’s Single Technology Appraisal process, was to review the evidence for the clinical and cost-effectiveness of Ranibizumab for treating choroidal neovascularisation associated with pathological myopia. The main source of clinical evidence submitted by the company (Novartis) responsible for manufacturing Ranibizumab (Lucentis) consisted of one phase III trial comparing Ranibizumab with verteporfin photodynamic therapy (vPDT) in people with visual impairment caused by choroidal neovascularisation secondary to pathological myopia. The Aberdeen HTA Group acted as the Evidence Review Group (ERG) for the project and provided an independent critique of the clinical and cost-effectiveness submitted by the company.
After taking into consideration the company submission and the findings of the ERG’s critique, NICE released clinical guidance (TA298, November 2013). Ranibizumab is currently recommended by NICE as an option for treating visual impairment due to choroidal neovascularisation secondary to pathological myopia when the manufacturer provides Ranibizumab in line with the commercial access agreement with NHS England.
Miriam Brazzelli: email@example.com
Cummins, E, Fielding, S, Cruickshank, M, Fraser, C, Lois, N, Brazzelli, M. Ranibizumab for the treatment of choroidal neovascularisation associated with pathological myopia. A Single Technology Appraisal. Evidence Review Group report in support of NICE STA programme. University of Aberdeen: Health Services Research Unit; 2013 URL: https://www.nice.org.uk/guidance/ta298/documents/choroidal-neovascularisation-pathological-myopia-ranibizumab-evaluation-report2